Atlantic Shores reaffirms commitment to New Jersey offshore wind despite Shell's write-off
Jan 30 (Reuters) - Atlantic Shores, a joint venture between Shell Plc (SHEL.L), opens new tab and France's EDF, reiterated its commitment to delivering New Jersey's first offshore wind project on Thursday, despite Shell's recent $1 billion write-off related to the venture.
Shell's fourth-quarter earnings included $2.2 billion in impairments, part of which was a $1 billion write-off for Atlantic Shores, with Chief Financial Officer Sinead Gorman stating that the project did not align with the company's capabilities or return goals. Shell is now looking to monetize its stake.
Atlantic Shores had submitted a proposal in July last year to supply offshore wind energy to New Jerse y as part of the state's Fourth Offshore Wind Solicitation.
In response to Shell's write-off, Atlantic Shores affirmed its dedication to progressing with the project, emphasizing its compliance with obligations to local, state and federal partners under existing leases and permits, the company said in a statement.
"Business plans, projects, portfolio projections, and scopes evolve over time – and as expected for large, capital-intensive infrastructure projects like ours, our shareholders have always prepared long-term strategies that contemplate multiple scenarios that enable Atlantic Shores to reach its full potential," the company stated.
The Atlantic Shores South wind project is expected to generate up to 2,800 megawatts of electricity, enough to power close to 1 million homes, according to the U.S. Interior Department.
However, the broader offshore wind sector has faced significant economic challenges, including soaring materials costs, high interest rates and supply-chain delays.
Several major developers, including Orsted, Equinor (EQNR.OL), opens new tab, BP (BP.L), opens new tab, Avangrid and Shell, have canceled or sought to renegotiate power contracts for planned U.S. wind farms with expected start dates between 2025 and 2028.
Offshore wind remains a target, as new U.S. President Donald Trump is set to follow through on his pledge to halt such projects, creating ongoing uncertainty for the industry.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
38 minutes ago
- Telegraph
NHS drug charges row hits deadlock
Ministers have failed to agree a crucial deal on NHS drug charges that was meant to be at the centre of a plan to boost growth. Talks on Friday between the Government and pharmaceutical industry bosses ended without an agreement on how much the NHS is able to claw back in rebates on drugs. Ministers had been hoping to be able to address industry complaints of unfairness prior to the publication a strategy for the sector, expected next week. One senior pharmaceutical executive said: 'If a [NHS clawback] deal is not secured, it's a missed opportunity for the life sciences sector plan and one which blocks the UK's ambition to be a life sciences superpower.' Another said that the UK needed to show it wanted to make the scheme competitive again, adding: 'Without that, all the high statements of ambition or new strategies in the world are not going to make the UK a leading life sciences centre.' The Department of Health launched a review of NHS rebates earlier this year under pressure from Donald Trump and the pharmaceutical industry. Ministers said they would take into account the 'concerns of the US president' that countries are unfairly keeping prices low relative to the high drug costs in the American health system. Under the trade agreement signed between the two nations earlier this year, the Government agreed to 'endeavour to improve the overall environment for pharmaceutical companies operating in the UK'. The failure to secure a deal ahead of the publication of the sector strategy follows months of wrangling. Under the current rebate scheme, known as VPAG, pharmaceutical companies have to hand at least 23pc of their revenue from sales of branded medicines back to the NHS. The scheme cut the drug bill by £3bn last year. However, pharmaceutical bosses have warned the scheme is preventing the launch of cutting-edge medicines in the UK. They have pressed for the UK to cut the rate of rebates into single digits, a level seen elsewhere in Europe. The life sciences strategy is one of several sector plans announced as part of Labour's industrial strategy. Others were published this week. A spokesman for the Government said: 'Economic growth is our number one priority and we're taking decisive action to unlock innovation and drive investment in the UK's world-class pharmaceutical sector. As part of this, we continue to work closely with industry on a rapid review of our voluntary scheme for medicines pricing. 'With our work and investment, we will make sure the next game changers in medicine are developed here in Britain, for the benefit of our health at home and abroad.'
The Guardian
an hour ago
- The Guardian
Trump says he is ending Canada trade talks amid tech tax dispute
Donald Trump has announced he is ending trade talks with Canada, one of its largest trading partners, accusing it of imposing unfair taxes on US technology companies in a 'direct and blatant attack on our country'. The news came hours after the US had announced a breakthrough in talks with China over rare-earth shipments into America, and announcements from top officials that the US would continue trade negotiations beyond a 9 July deadline set by Trump. Signs of a cooling in the trade war sent US stock markets to new highs. The US has been negotiating a trade deal with Canada, one of its top two global trading partners, for months. Mark Carney, Canada's prime minister, met Trump at the G7 summit of world leaders in Alberta earlier this month. Carney announced that Trump had agreed to 'pursue negotiations toward a deal within the coming 30 days'. But talks appear to have foundered over Canada's decision to impose a digital services tax on US technology companies. First payments on the tax are due on Monday. Trump wrote on Truth Social: 'We have just been informed that Canada, a very difficult Country to TRADE with, including the fact that they have charged our Farmers as much as 400% Tariffs, for years, on Dairy Products, has just announced that they are putting a Digital Services Tax on our American Technology Companies, which is a direct and blatant attack on our Country. 'They are obviously copying the European Union, which has done the same thing, and is currently under discussion with us, also. Based on this egregious Tax, we are hereby terminating ALL discussions on Trade with Canada, effective immediately. We will let Canada know the Tariff that they will be paying to do business with the United States of America within the next seven day period. 'Thank you for your attention to this matter!'
BBC News
an hour ago
- BBC News
Trump says he is cutting off trade talks with Canada
US President Donald Trump has said he is cutting off trade talks with Canada "immediately" as the country looks to start enforcing a tax policy targeting big tech companies. The latest move, which he announced on social media, comes as the neighbouring nations had been working to agree a trade deal by countries have imposed tariffs on each other's goods after Trump sparked a trade war earlier this year and threatened to annex Canada using "economic force".On Friday, the US president said he was ending talks due to what he called an "egregious tax" on tech companies. He said he would announce new tariffs on goods crossing the border within the next week. "We are hereby terminating ALL discussions on Trade with Canada, effective immediately," he wrote on social media. "We will let Canada know the Tariff that they will be paying to do business with the United States of America within the next seven day period."
